Добірка наукової літератури з теми "Precision cancer therapy"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Precision cancer therapy".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Precision cancer therapy"
Nalley, Catlin. "Precision Therapy in Lung Cancer." Oncology Times 42, no. 18 (September 20, 2020): 21. http://dx.doi.org/10.1097/01.cot.0000717748.60516.e7.
Повний текст джерелаAl-Janabi, Ismail. "Pharmacogenomics Driving Precision Cancer Medicine." Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 ) 3 (October 24, 2022): 48–63. http://dx.doi.org/10.54133/ajms.v3i.85.
Повний текст джерелаWong, Ada Hang-Heng, and Chu-Xia Deng. "Precision Medicine for Personalized Cancer Therapy." International Journal of Biological Sciences 11, no. 12 (2015): 1410–12. http://dx.doi.org/10.7150/ijbs.14154.
Повний текст джерелаKato, Shumei, and Razelle Kurzrock. "An avatar for precision cancer therapy." Nature Biotechnology 36, no. 11 (November 2018): 1053–55. http://dx.doi.org/10.1038/nbt.4293.
Повний текст джерелаDummer, Reinhard. "Precision medicine and skin cancer therapy." Current Opinion in Oncology 26, no. 2 (March 2014): 182–83. http://dx.doi.org/10.1097/cco.0000000000000059.
Повний текст джерелаThomas, Anish. "More precision in lung cancer therapy." Science Translational Medicine 7, no. 287 (May 13, 2015): 287ec79. http://dx.doi.org/10.1126/scitranslmed.aab3977.
Повний текст джерелаSchiff, Joshua P., Pedro C. Barata, Evan Y. Yu, and Petros Grivas. "Precision therapy in advanced urothelial cancer." Expert Review of Precision Medicine and Drug Development 4, no. 2 (March 4, 2019): 81–93. http://dx.doi.org/10.1080/23808993.2019.1582298.
Повний текст джерелаSapiezynski, Justin, Oleh Taratula, Lorna Rodriguez-Rodriguez, and Tamara Minko. "Precision targeted therapy of ovarian cancer." Journal of Controlled Release 243 (December 2016): 250–68. http://dx.doi.org/10.1016/j.jconrel.2016.10.014.
Повний текст джерелаMeiliana, Anna, Nurrani Mustika Dewi, and Andi Wijaya. "CAR T Cells: Precision Cancer Immunotherapy." Indonesian Biomedical Journal 10, no. 3 (December 28, 2018): 203–16. http://dx.doi.org/10.18585/inabj.v10i3.635.
Повний текст джерелаHenscheid, Nick, Eric Clarkson, Kyle J. Myers, and Harrison H. Barrett. "Physiological random processes in precision cancer therapy." PLOS ONE 13, no. 6 (June 29, 2018): e0199823. http://dx.doi.org/10.1371/journal.pone.0199823.
Повний текст джерелаДисертації з теми "Precision cancer therapy"
Mooney, Marie R. "Precision Medicine Approaches to Integrating Genomics with Cancer Therapy| Applications in Glioblastoma and Lymphoma." Thesis, Van Andel Research Institute, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10275288.
Повний текст джерелаThe word "cancer" rarely stands alone, usually prefaced with its anatomical location: lung cancer, prostate cancer, brain cancer. With the advancement of high-throughput omics approaches, specific oncogenic events are reorganizing the landscape of cancer classification, at once creating commonalities between cancers arising in diverse anatomical locations and dividing organ-centric classifications of cancer into a multitude of subtypes. The term "precision medicine" postulates that these new, data-driven groupings based on molecular characterization are the key to making rational therapeutic choices.
The majority of this dissertation addresses the disconnect between extensive molecular characterization and poor cancer therapy outcomes for patients with glioblastoma multiforme (GBM). Despite clear evidence that hyperproduction of the ligand for PDGFR (platelet-derived growth factor receptor α) is sufficient to generate GBM of the proneural subtype, anti-PDGFRα therapeutics have proven disappointing in clinical trials. Cell adaptation contributes to therapeutic escape. In GBM, proneural tumor cells adopt transcriptional profiles of the mesenchymal subtype. The interconversion between the proneural and mesenchymal transcriptional classes within a tumor population presents both a challenge and an opportunity for therapeutic approaches. The proneural subtype has a proliferation phenotype and presents druggable targets such as PDGFRα. The mesenchymal subtype presents an invasive phenotype, but the targets are more challenging to drug. The typical screening for combination therapies that synergize to induce cell death is not as advantageous here, where the disease management is expected to include cytostatic drugs that act on two different aspects of the phenotype: proneurally mediated proliferation and mesenchymally mediated invasion. This work examines the applicability of a combination approach against a proneural target, PDGFRα, and mesenchymal targets in the STAT3 (signal transducer and activator of transcription 3) pathway, in the context of a proneural model of GBM.
The work is concluded with collection of work applying precision medicine in other disease contexts, most notably canine lymphoma.
Jacobson, Timothy. "A Trans-Dimensional View of Drug Resistance Evolution in Multiple Myeloma Patients." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6099.
Повний текст джерелаMansinhos, Inês Filipa Paixão. "Detection of new actionable mutations in lung cancer precision therapy." Master's thesis, 2017. http://hdl.handle.net/10316/82998.
Повний текст джерелаO cancro de pulmão é a causa mais comum de morte por cancro, em todo o mundo, em ambos os sexos. Cerca de 80% a 85% dos casos de cancro de pulmão são pacientes com cancro de pulmão de não pequenas células (CPNPC), sendo os restantes 15% -20% cancro de pulmão de pequenas células (CPPC). O CPNPC é dividido em três grupos: adenocarcinoma, carcinoma de células escamosas e carcinoma de células grandes. Entre eles, os casos de adenocarcinoma representam cerca de 40 a 50% dos pacientes com CPNPC. O prognóstico para CPNPC é baixo, com uma taxa de sobrevivência de cinco anos inferior a 20% sendo esta, ainda, pior para o CPPC, com uma taxa de sobrevivência de cinco anos inferior a 5%.Durante muito tempo, os tratamentos de primeira linha foram a cirurgia, a quimioterapia ou a radioterapia. No entanto, a descoberta de várias mutações drivers da carcinogénese em pacientes com CPNPC, especialmente em casos de adenocarcinoma, permitiu o desenvolvimento de tratamentos personalizados com base nessas alterações moleculares específicas. Deste modo, as mutações no EGFR (Recetor do Fator de Crescimento Epidérmico) representam até 15% dos adenocarcinomas e ocorrem principalmente no domínio tirosina quinase (TK) do gene. Mais de 80% dessas mutações consistem em deleções in-frame no exão 19 e na mutação pontual L858R no exão 21. Tais mutações induzem uma ativação constitutiva do EGFR, tornando-se um potencial alvo terapêutico. Assim, os pacientes portadores de mutações no EGFR podem beneficiar de um tratamento específico de primeira linha, mais especificamente, de inibidores de TK (TKI) que, de forma competitiva, inibem a fixação da adenosina trifosfato (ATP) ao local de ligação catalítica do domínio TK. Foram, também, propostos outros driver biomarcadores em cancro de pulmão podendo, alguns deles, fornecer informações adicionais para a tomada de decisões clínicas.Desta forma, o objetivo principal deste projeto foi avaliar mutações noutros alvos potencialmente acionáveis - MET e ERBB2 - em pacientes com adenocarcinoma, através da sequenciação de Sanger, e desenvolver um ensaio multiplex de PCR em tempo real, para uma rápida e sensível avaliação do estado mutacional em tecido e em plasma. Este ensaio também dará a oportunidade de monitorizar a evolução do estado mutacional no plasma durante o tratamento, para a predição de recidiva e controlo do aparecimento de clones com mutações de resistência.Do total de 172 amostras, 161 (88,9%) foram classificadas como negativas para alterações nos exões 18, 19, 20 e 21 do EGFR, enquanto 19 (11,1%) foram classificadas como positivas. No total das 19 alterações encontradas no EGFR, 73,7% foram deleções no exão 19 e 21% relataram a mutação Leu858Arg. Um caso de uma alteração T790M foi, também, encontrado num paciente. Numa frequência mais baixa, um caso Leu861Gln também foi relatado. No gene MET, as mesmas 172 amostras foram, igualmente, analisadas. Destas, 9 amostras (5,2%) apresentaram alterações no gene, incluindo 2 variantes intrónicas, 2 mutações indel e 5 mutações pontuais, no exão 14. As alterações no ERBB2 foram analisadas em 69 amostras, tendo sido detetado um caso de inserção de 12 bases no exão 20.Este trabalho permitiu concluir que uma proporção importante de casos apresenta mutações no MET e ERBB2, sendo que tais pacientes poderiam ser tratados com fármacos aprovados para esses alvos.
Lung cancer is the most common cause of cancer death around the world, in both sex. About 80%–85% of lung cancer cases are non-small-cell lung cancer (NSCLC) patients, the remaining 15%–20% are small-cell lung cancer (SCLC). NSCLC is divided into three categories called: adenocarcinoma, squamous-cell carcinoma and large cell carcinoma. Among them, adenocarcinoma cases account for around 40-50% of NSCLC patients. The prognosis for NSCLC is low with a five-year survival rate of less than 20%, and is even worse for SCLC with a five-year survival rate of less than 5%.For a long time, the first-line treatments have been surgery, chemotherapy or radiotherapy. However, the discovery of several oncogenic driver mutations in patients with NSCLC, adenocarcinoma cases in particular, has allowed the development of personalized treatments based on these specific molecular alterations. Therefore, EGFR (epidermal growth factor receptor) mutations account for up to 15% of adenocarcinoma and primarily occurred in the tyrosine kinase (TK) domain of the gene. More than 80% of these mutations consist of in-frame deletions in exon 19 and the L858R point mutation in exon 21. Such mutations induced a constitutive activation of EGFR, making it a potential therapeutic target. Thus, EGFR-mutated patients can benefit from a specific first-line treatment specifically the TK inhibitors (TKI) that competitively inhibits fixation of adenosine triphosphate (ATP) in the catalytic binding site of TK domain. Other driver biomarkers in lung cancer have also been proposed and some of them might provide additional information for clinical decision-making. In this way, the main goal of this project was to evaluate mutations in other potentially actionable targets – MET and ERBB2– in patients with adenocarcinoma by Sanger sequencing and to develop a Real Time PCR multiplex assay for rapid sensitive assessment of mutation profile in tissue and plasma. This assay, will also give the opportunity to monitor the evolution of mutational status in the plasma during the treatment for the prediction of relapse and control the appearance of clones with resistance mutations.Of the total of 172 samples, 161 (88.9%) were classified as negative for alterations in exons 18, 19, 20 and 21 of EGFR, whereas 19 samples (11.1%) were classified as positive. In total of the 19 alterations in EGFR, 73.7% were deletions in exon 19 and 21% was related to Leu858Arg mutation. A case of a T790M alteration was also founded in a patient. At a lower frequency, a case of a Leu861Gln was also reported. In MET gene, the same 172 samples were, also, analyzed. Of these, 9 samples (5.2%) harbored alterations in MET gene, including 2 intronic variants, 2 indel mutations and 5 pontual mutations in exon 14. ERBB2 alterations were analyzed in 69 samples and one case of an insertion of 12 bases in exon 20 were detected.This work allowed us to conclude that an important proportion of cases harbors mutations in MET and ERBB2 and these patients could potentially be treated with approved drugs for these targets.
Perera-Bel, Julia. "Guiding Cancer Therapy: Evidence-driven Reporting of Genomic Data." Doctoral thesis, 2018. http://hdl.handle.net/11858/00-1735-0000-002E-E511-6.
Повний текст джерелаMartins, Catarina Fortunato. "Laser ablation of tumour cells via precision nanomedicine." Master's thesis, 2021. http://hdl.handle.net/10362/125768.
Повний текст джерелаCancer is defined as a complex set of diseases that affect the multiplication of cells, being one of the leading causes of mortality worldwide. Although several types of cancer therapies are available, the most used to treat cancer are surgery and chemotherapy, both with several side effects and limited to certain types of cancer. Nanomedicine is the sci-ence and technology field that uses nanoscale systems to diagnose, treat, or prevent a disease. Gold nanoparticles (AuNPs) are highly used in biomedical applications due to their physical-chemical properties like biocompatibility, high surface-area-to-volume ra-tio, and ease of functionalization. AuNPs are mainly used in photothermal therapy, since the radiation will trigger a thermal photo conversion, destroying cancer cells thus reduc-ing the tumour volume. Gene therapy has emerged as an excellent approach to cancer therapy, using genes to treat a disease using oncogenes or tumour suppressors. c-MYC is an oncogene widely studied, whose expression is deregulated in various cancers, being involved in cell proliferation, growth, and metabolism. Thus, it was suggested a combi-natory therapy, exploring the AuNPs as "theranostic" systems, between gene therapy and photothermal therapy. The results achieved of the synergy of both therapies indicate that hyperthermia enhances the cell permeability, thus increasing the gene silencing of the c-MYC by almost 70%.
Marques, Lúcia Deodata António Martins. "Cancer therapy : a focus on gut microbiota." Master's thesis, 2019. http://hdl.handle.net/10451/43238.
Повний текст джерелаO cancro é uma doença com um grande impacto em todo o mundo, contribuindo de forma significativa para a mortalidade e a morbidade. Apesar da disponibilidade de vários tratamentos e o aparecimento de novas terapêuticas, este ainda é uma das principais causas de morte. O tratamento desta doença consiste num equilíbrio frágil entre a eficácia e os efeitos colaterais, sendo que alguns tratamentos podem ser responsáveis por uma toxicidade considerável, comprometendo a qualidade de vida dos doentes e reduzindo a intensidade de dose, o que em última instância pode comprometer o resultado. Esta revisão tem como objetivo recolher informação sobre a associação entre a terapêutica oncológica e microbiota intestinal. Não só a microbiota intestinal poderá trazer esperança para áreas como prevenção, diagnóstico precoce e prognóstico do cancro, mas também ter o intuito de otimizar a terapêutica oncológica, melhorando o perfil de toxicidade, aumentando a eficácia do tratamento e até mesmo levando ao desenvolvimento de novos tratamentos. A microbiota intestinal também poderia explicar parcialmente a resistência à terapêutica em alguns doentes, bem como as diferenças entre as respostas intra e interpessoal do hospedeiro, evidenciando a magnitude que a caracterização e a manipulação do microbioma poderia adicionar à terapêutica individualizada de cada doente. Em conclusão, a modulação da microbiota intestinal, através da suplementação com determinados probióticos, prebióticos ou ambos, dieta ou mesmo através do transplante de microbiota fecal, poderá tornar possível a personalização da microbiota intestinal dos doentes, a fim de melhorar as suas respostas e alcançar melhores resultados no tratamento do cancro. Apesar de grandes feitos terem sido alcançados nesta área, uma maior consciencialização, pesquisa e validação da transposição de dados são necessárias para aplicar com segurança a medicina de precisão relacionada com a microbiota na prática clínica diária.
Cancer is responsible for a major burden of disease worldwide, contributing for both mortality and morbidity. Despite the availability of several cancer treatments and the arise of novel therapies, cancer is still a major cause of death. Cancer treatment is always a fragile balance between efficacy and side effects, with some treatments being able to cause significant side effects that compromise patients’ quality of life and, ultimately, reduce dose intensity, which could compromise the outcome. This review aims to gather information about the association between cancer therapy and gut microbiota. Not only gut microbiota could bring hope to areas like prevention, early diagnostic and prognostic of cancer, but could also improve cancer treatment, by ameliorating side effects, enhancing treatment efficacy and hopefully lead to the development of new therapies. Gut microbiota could also partially explain therapy resistance in some patients and the differences between intra and interpersonal host responses, evidencing the magnitude that microbiome characterization and manipulation could add to individual care. Modulation of gut microbiota, through antibiotics, supplementation with certain prebiotics, probiotics or both, diet or even through fecal microbiota transplant, could customize the patients’ microbiota with the objective of improving their outcomes and reducing side effects. Even though great steps have been made, further awareness, research and validation of data transposition are necessary to safely apply microbiota precision medicine into daily clinical practice.
Tillner, Falk. "Das Bildgeführte Präzisionsbestrahlungsgerät für Kleintiere (SAIGRT): von der Entwicklung bis zur Praxisreife." 2019. https://tud.qucosa.de/id/qucosa%3A70604.
Повний текст джерелаThe Small Animal Image-Guided Radiation Therapy (SAIGRT) platform facilitates fast, high resolution X-ray imaging and precise, conformal irradiation of small animals in preclinical in-vivo experiments for translational cancer research. Dedicated software for device control as well as image correction and reconstruction on a central high performance PC provide all device functions and allow simple and safe operation by automated procedures and intuitive graphical user interfaces. A fully 3D treatment planning software adapted from human clinical radiation therapy is used for treatment planning, containing established tools and methods for the transfer and registration of multimodality imaging data, contouring and segmentation of target volumes and organs at risk as well as creation and evaluation of treatment plans. Based on an individual CT scan of the small animal and a machine model adapted for the SAIGRT, the resulting dose distribution is simulated by a Monte-Carlo algorithm in a precise and realistic manner. Geometrical calibrations as well as manifold basic data measurements for X-ray imaging and irradiation during commissioning resulted in a targeting and imaging accuracy of about ±0.1 mm, a correct representation of imaging geometry and a good image quality with imaging doses comparable with those of clinical radiography and CT systems. Dose distribution of the defined beam quality used for irradiation of small animals reflects a downsized human radiation therapy using high energy photon beams of clinical linear accelerators. A comprehensive quality assurance program comprising regular maintenance and periodic constancy tests of X-ray imaging and irradiation ensures permanent technically perfect condition and proper availability of all implemented functions in a stable high quality. The SAIGRT platform is feasible for image-guided irradiations precisely applied to small animals in preclinical in-vivo experiments using a workflow of modern human radiation oncology. Thus, it significantly contributes to translational cancer research by more realistic modelling the clinical situation and potentially brings the results closer to their clinical implementation.
Ferreira, Mariana Catarina Andrade. "Imunoterapia do cancro." Master's thesis, 2019. http://hdl.handle.net/10284/7703.
Повний текст джерелаCancer appears as one of the most prevalent, incidental and deadly diseases of the present time, being cancer of the lung, breast, prostate and colorectal the ones with more incidence. In Portugal, particularly in the North and in the female gender, there is also cancer of the thyroid and stomach. The immune system has the function of maintaining the body's homeostasis through a collective and coordinated response of cells, tissues, organs and molecules responsible for eliminating threats to the proper functioning of the human body. However, some pathologies may affect the effectiveness of the immune system, such as neoplasms which arise from the accumulation of mutations in cells that the body, for some reason, can not repair or eliminate from the cell cycle. Factors such as inflammation, tumor microenvironment, the cells that make up the immune system, predisposition to genetic factors and exposure to certain carcinogenic agents, potentiate the appearance of neoplasm. For this, it is necessary to understand the role of each of them, in order to be able to direct, optimize and develop more effective therapies. In this sense, a new form of therapy arises, different from the conventional ones, with less toxicity and adverse effects, that uses the organism’s cells to fight the disease, the immunotherapy. Therapies such as, Immunological Checkpoint involving two monoclonal antibodies, Cellular and Adoptive Transfer and Tumor Vaccines, are part of this innovation and nowadays it shows very promising results in some tumor models. Therefore, the concept of precision medicine also arises where it is possible to create specific profiles for a particular patient with a particular type of cancer.
Книги з теми "Precision cancer therapy"
Von Hoff, Daniel D., and Haiyong Han, eds. Precision Medicine in Cancer Therapy. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4.
Повний текст джерелаHoff, Daniel D. Von, and Haiyong Han. Precision Medicine in Cancer Therapy. Springer, 2019.
Знайти повний текст джерелаHoff, Daniel D. Von, and Haiyong Han. Precision Medicine in Cancer Therapy. Springer International Publishing AG, 2020.
Знайти повний текст джерелаChick Chorioallantoic Membrane Model and Precision Cancer Therapy. Elsevier, 2019. http://dx.doi.org/10.1016/s1874-6047(19)x0003-7.
Повний текст джерелаTamanoi, Fuyuhiko. Chick Chorioallantoic Membrane Model and Precision Cancer Therapy. Elsevier Science & Technology, 2019.
Знайти повний текст джерелаTamanoi, Fuyuhiko. Chick Chorioallantoic Membrane Model and Precision Cancer Therapy. Elsevier Science & Technology Books, 2019.
Знайти повний текст джерелаGiordano, Antonio, and Vincenzo Canzonieri. Gastric Cancer In The Precision Medicine Era: Diagnosis and Therapy. Springer, 2019.
Знайти повний текст джерелаSoares, Christiane Pienna, Zhi Ping (Gordon) Xu, Ângela Sousa, and Hernane Da Silva Barud, eds. Nanotechnology for Precision Cancer Therapy: Advances in gene therapy, immunotherapy, and 3D bioprinting. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-821-4.
Повний текст джерелаFleck, Leonard M. Precision Medicine and Distributive Justice. Oxford University PressNew York, 2022. http://dx.doi.org/10.1093/oso/9780197647721.001.0001.
Повний текст джерелаЧастини книг з теми "Precision cancer therapy"
Gatalica, Zoran, Rebecca Feldman, Semir Vranić, and David Spetzler. "Immunohistochemistry-Enabled Precision Medicine." In Precision Medicine in Cancer Therapy, 111–35. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_4.
Повний текст джерелаLee, John K., and Saul J. Priceman. "Precision Medicine-Enabled Cancer Immunotherapy." In Precision Medicine in Cancer Therapy, 189–205. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_7.
Повний текст джерелаRoos, Alison, and Sara A. Byron. "Genomics-Enabled Precision Medicine for Cancer." In Precision Medicine in Cancer Therapy, 137–69. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_5.
Повний текст джерелаHill, Addie, Rohan Gupta, Dan Zhao, Ritika Vankina, Idoroenyi Amanam, and Ravi Salgia. "Targeted Therapies in Non-small-Cell Lung Cancer." In Precision Medicine in Cancer Therapy, 3–43. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_1.
Повний текст джерелаGately, Stephen. "Human Microbiota and Personalized Cancer Treatments: Role of Commensal Microbes in Treatment Outcomes for Cancer Patients." In Precision Medicine in Cancer Therapy, 253–64. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_10.
Повний текст джерелаSchork, Nicholas J. "Artificial Intelligence and Personalized Medicine." In Precision Medicine in Cancer Therapy, 265–83. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_11.
Повний текст джерелаSachdev, Jasgit C., Ana C. Sandoval, and Mohammad Jahanzeb. "Update on Precision Medicine in Breast Cancer." In Precision Medicine in Cancer Therapy, 45–80. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_2.
Повний текст джерелаDemeure, Michael J. "The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers." In Precision Medicine in Cancer Therapy, 81–108. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_3.
Повний текст джерелаPierobon, Mariaelena, Julie Wulfkuhle, Lance A. Liotta, and Emanuel F. Petricoin III. "Utilization of Proteomic Technologies for Precision Oncology Applications." In Precision Medicine in Cancer Therapy, 171–87. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_6.
Повний текст джерелаKorn, Ronald L., Syed Rahmanuddin, and Erkut Borazanci. "Use of Precision Imaging in the Evaluation of Pancreas Cancer." In Precision Medicine in Cancer Therapy, 209–36. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16391-4_8.
Повний текст джерелаТези доповідей конференцій з теми "Precision cancer therapy"
Kothari, Vishal, Wei Iris, Sunita Shankar, Shanker Kalyana-Sundaram, Lidong Wang, Linda W. Ma, Pankaj Vats, et al. "Abstract PR16: Targeting cancer-specific kinase dependency for precision therapy." In Abstracts: AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities - May 17-20, 2013; Bellevue, WA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.pms-pr16.
Повний текст джерелаLiu, Xuefeng. "Abstract LB-222: Culturing cancer cells from liquid biopsies for precision cancer therapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-lb-222.
Повний текст джерелаD'Andrea, Alan D. "Abstract IA12: Targeting DNA repair in cancer therapy." In Abstracts: AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1557-3265.pmccavuln16-ia12.
Повний текст джерелаAshworth, Alan. "Abstract IA14: Harnessing genetic dependencies in cancer therapy." In Abstracts: AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities - May 17-20, 2013; Bellevue, WA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.pms-ia14.
Повний текст джерелаHwa, KuoYuan, and Kreeti Kajal. "Design for an in silico Platform of Precision Medicine on Cancer Therapy." In the 2018 5th International Conference. New York, New York, USA: ACM Press, 2018. http://dx.doi.org/10.1145/3301879.3301904.
Повний текст джерелаHerman, Jacob A., Patrick J. Paddison, Jennifer DeLuca, and James Olson. "Abstract B27: Kinetochore-microtubule attachments as a precision therapy target." In Abstracts: AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; February 28 - March 2, 2016; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3125.cellcycle16-b27.
Повний текст джерелаSawyers, Charles L. "Abstract IA22: Reflections on precision medicine." In Abstracts: AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; June 13-16, 2015; Salt Lake City, UT. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3265.pmsclingen15-ia22.
Повний текст джерелаChantrill, Lorraine, Skye Simpson, Amber Johns, Mona Martyn-Smith, Angela Chou, Clare Watson, Adnan Nagrial, et al. "Abstract CT210: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-ct210.
Повний текст джерелаPuca, Loredana, Wouter R. Karthaus, Dong Gao, John Wongvipat, Andrea Sboner, Marcello Gaudiano, Chantal Pauli, et al. "Abstract 3098: Epigenetic therapy to target neuroendocrine prostate cancer using precision medicine models." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3098.
Повний текст джерелаAhmadi, Saba, Pattara Sukprasert, Rahulsimham Vegesna, Sanju Sinha, Natalie Artzi, Samir Khuller, Alejandro A. Schäffer, and Eytan Ruppin. "Abstract 2688: The landscape of precision cancer combination therapy: a single-cell perspective." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-2688.
Повний текст джерелаЗвіти організацій з теми "Precision cancer therapy"
Skelly, Andrea C., Roger Chou, Joseph R. Dettori, Erika D. Brodt, Andrea Diulio-Nakamura, Kim Mauer, Rongwei Fu, et al. Integrated and Comprehensive Pain Management Programs: Effectiveness and Harms. Agency for Healthcare Research and Quality (AHRQ), October 2021. http://dx.doi.org/10.23970/ahrqepccer251.
Повний текст джерела